In an early-phase trial, the BTK inhibitor led to an overall response in most patients with heavily pretreated CLL or SLL, but infections, bleeding, and neutropenia were common.
Identifying a Clear Path Through the Changing Maze of AML Management healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
The CAR T-cell therapy lisocabtagene maraleucel produced rapid and durable responses in heavily pretreated patients with relapsed/refractory mantle cell lymphoma.
CHICAGO — The addition of venetoclax to ibrutinib and obinutuzumab did not extend PFS among older patients with treatment-naive chronic lymphocytic leukemia during the COVID-19 pandemic, according to data presented at ASCO Annual Meeting. Long-term follow-up of the phase 3 study is underway to determine potential advantages of the three-drug combination in other settings, researchers wrote.
CHICAGO — Trastuzumab deruxtecan showed clinically meaningful activity against several types of HER2-expressing solid tumors, according to interim results of the DESTINY-PanTumor02 study presented at ASCO Annual Meeting.The HER2-directed antibody-drug conjugate, also known as T-DXd (Enhertu; AstraZeneca, Daiichi Sankyo), demonstrated the highest objective response rates and most durable